文献速递类风湿关节炎

托珠单抗治疗类风湿关节炎的转氨酶水平与肝脏事件:长期临床试验安全性数据汇总分析

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2017-08-01

该汇总分析纳入4171例接受静脉托珠单抗治疗的类风湿关节炎患者,共16204.8患者年暴露。转氨酶升高常见(ALT>ULN 70.6%,AST>ULN 59.4%),但肝脏严重不良事件率低(0.04/100患者年,95%CI 0.02-0.09)。建议定期监测,持续升高时调整托珠单抗/改善病情抗风湿药剂量。

要点

  • 托珠单抗治疗中ALT/AST升高常见,多数发生于治疗第一年。
  • ALT/AST>3×ULN者中80%恢复正常,中位恢复时间5.6周。
  • 肝脏严重不良事件发生率低,为0.04/100患者年(95%CI 0.02-0.09)。

核心结论

  • 托珠单抗治疗类风湿关节炎时转氨酶升高频繁,但肝脏严重不良事件率低。

研究设计与样本

  • 汇总分析纳入Ⅲ期或Ⅳ期临床试验、长期扩展研究及药理学研究中接受静脉托珠单抗(4、8或10 mg/kg,联用或不联用改善病情抗风湿药)的4171例患者,共16204.8患者年暴露(平均暴露时长3.9±2.0年)。

主要发现

  • ALT和AST高于正常上限(ULN)者分别占70.6%和59.4%。
  • ALT/AST升高>1-3×ULN者分别占59%/55%,>3-5×ULN者分别占8.9%/3.3%,>5×ULN者分别占2.9%/0.9%。
  • 单次ALT/AST>3×ULN者分别占7.7%/3.6%,连续≥2次>3×ULN者分别占1.9%/0.4%。
  • >3×ULN的升高在80%患者中恢复正常,中位恢复时间5.6周。
  • 2.5%患者因ALT/AST升高退出托珠单抗治疗;共发生7例肝脏严重不良事件(0.04/100患者年,95%CI 0.02-0.09)。

关键数值与推荐

  • 推荐定期监测转氨酶,对持续升高者调整托珠单抗/改善病情抗风湿药剂量。

临床怎么用

  • 托珠单抗治疗类风湿关节炎期间应定期监测转氨酶,尤其治疗第一年。
  • 对持续转氨酶升高者,考虑调整托珠单抗或联用改善病情抗风湿药的剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate liver enzyme abnormalities and hepatic adverse events (AEs) during long-term tocilizumab treatment for rheumatoid arthritis in clinical trials. METHODS: Data were pooled from patients who received intravenous tocilizumab (4, 8, or 10 mg/kg with or without disease-modifying antirheumatic drugs [DMARDs]) in phase III or IV clinical trials, long-term extensions, and a pharmacology study. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured routinely in these trials. AE rates were measured per 100 patient-years of tocilizumab exposure for this pooled analysis. RESULTS: Overall, 16,204.8 patient-years of tocilizumab exposure (mean ± SD duration of exposure 3.9 ± 2.0 years) were evaluated for 4,171 patients. ALT and AST elevations greater than the upper limit of normal (ULN) occurred in 70.6% and 59.4% of patients, respectively. ALT/AST elevations were >1-3× ULN in 59%/55% of patients, >3-5× ULN in 8.9%/3.3% of patients, and >5× ULN in 2.9%/0.9% of patients. Most elevations occurred during the first year of treatment. Single ALT/AST elevations >3× ULN occurred in 7.7%/3.6% of patients, and ≥2 consecutive elevations >3× ULN occurred in 1.9%/0.4% of patients. Elevations >3× ULN returned to normal in 80% of patients (median of 5.6 weeks to normalization). A total of 2.5% of patients withdrew from tocilizumab treatment following ALT/AST elevations. A total of 7 hepatic serious AEs (SAEs) (0.04 per 100 patient-years [95% confidence interval 0.02-0.09]) occurred in the tocilizumab studies. CONCLUSION: Transaminase elevations with tocilizumab were frequent, but rates of hepatic SAEs were low in this clinical trial data set. Regular monitoring, with dose adjustment of tocilizumab/DMARDs for persistent elevations, is recommended.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Genovese MC, Kremer JM, van Vollenhoven RF, et al. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis Rheumatol. 2017. PMID: 28597609. doi:10.1002/art.40176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。